Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. There are specific places that remind us of an important ...

Abstract: Mathematics is filled with conjectures that involve infinite recursive structure, representing complex structures and underlying deep relationships. Discovering such conjectures is crucial ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time ...

Abstract: In the automation era, DC motors are widely utilized across various industries due to their adaptability and efficiency. In the downside of reality, accurately modelling and controlling ...